Tag archive for ‘Bristol-Myers Squibb’
Bristol-Myers Squibb: Side Effect Issue with Hepatitis C Drug Creates a Buying Opportunity (BMY, $32.55)
Side Effect Issue Leads to Sharp Price Drop Bristol-Myers disclosed on August 1, 2012 that it has suspended a phase II trial in hepatitis C in which BMS-986094, its nucleotide polymerase inhibitor, was being studied in combination with daclatasvir, its NS5a inhibitor. BMS-986094 has been broadly viewed as the cornerstone of BMY’s effort to develop […]
Bristol-Myers Squibb: Best Positioned for Growth of the Four Big US Pharma Companies
Bristol-Myers (BMY), Eli Lilly (LLY), Merck (MRK) and Pfizer (PFE) were out of favor for many years based on concerns about pricing and attempts to reduce drug utilization brought on by world economic pressures, lack of visibility on new products and pending patent cliffs. Each has patent expirations on major products that will essentially result […]
Amylin Acquisition is a Mild Positive for Bristol-Myers Squibb
I prefer growth through internal product development over growth through acquisition. It is the product pipeline that drives my buy recommendation on Bristol-Myers Squibb (BMY). The acquisition of Amylin (AMLN) has some tactical appeal as it strengthens BMY’s position in the diabetes market, is only modestly dilutive in the near term and could be quite […]
Bristol-Myers Squibb: Acquisition of Amylin is a Mild Posiitve (BMY, $35.89)
Investment Opinion I prefer growth through internal product development over growth through acquisition. It is the product pipeline that drives my buy recommendation on Bristol-Myers Squibb (BMY). The acquisition of Amylin (AMLN) has some tactical appeal as it strengthens BMY’s position in the diabetes market, is only modestly dilutive in the near term and could […]
Issuance of Complete Response Letter for Eliquis Doesn’t Alter My Buy on Bristol-Myers Squibb
Investment Opinion I believe that the issuance of a Complete Response Letter to Bristol-Myers Squibb (BMY) and Pfizer (PFE) for the use of Eliquis to prevent stokes caused by atrial fibrillation is a minor setback and believe that the issue can be resolved and the product approved by October at the earliest and April of […]
FDA Cardiovascular and Renal Advisory Committee Goes Against FDA View and Recommends Approval of Xarelto
The FDA had apparently slammed the door shut on approval of Johnson & Johnson’s Xarelto (rivaroxaban) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF). The FDA reviewer in his briefing papers to the committee had recommended that the product be given a Complete Response Letter (not approvable at this time). The reviewer did […]
FDA Advisory Committee Recommendation for Approval of Xarelto Bodes Well for Approval of Eliquis (apixaban)
The FDA had apparently slammed the door shut on approval of Johnson & Johnson’s Xarelto (rivaroxaban) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF). The FDA reviewer in his briefing papers to the committee had recommended that the product be given a Complete Response Letter (not approvable at this time). The reviewer did […]
Xarelto’s Problems are Eliquis’ Opportunities (BMY. $29.90)
Investment Opinion I have been on the fence in deciding whether to upgrade Bristol-Myers (BMY) to a Buy. The issues now facing rivaroxaban are all significantly to the benefit of BMY’s apixaban and cause me to go to a Buy on Bristol-Myers Squibb. The FDA problems encountered with rivaroxaban are a significant, but not crushing […]
New Product Potential is Outstanding But Patent Cliff is Looming (BMY, $29.28)
Investment Position My position on BMY is that patient investors can buy the stock for the dividend yield and wait for the projected resurgence in growth in 2013. I don’t own the stock yet, but I might be a buyer at some point. A potential catalyst for my decision is the anticipated release of full […]
Eliquis Could Be A Blockbuster (BMY, $29.46)
Introduction and Purpose of this Report I believe that the anti-coagulant drug market is poised to become the next blockbuster category in cardiovascular disease following the path of the hypertension and cholesterol drugs. This could mean that sales would reach several billions of dollars arising from several individual blockbuster products. If I am correct, there […]